Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 1

Research Article

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 1

Clinicopathological data of breast cancer patients.

VariablesBefore propensity matching After propensity matching
Group 1 ()Group 2 () Group 1 () Group 2 ()

Age, yr 50.3 (49.4–51.2)47.1 (46.1–48.1)0.00000449.8 (49.0–50.6)50.2 (49.3–51.0)0.504
Chemotherapy<0.00010.250
 115435179173
 242546352
 3172183229260
 4858710692
TNM stage0.45940.200
 I164117215164
 II219189275333
 III and IV70538780
Neoadjuvant chemotherapy0.00290.637
 Yes738894100
 No380271483477
ER0.0001490.899
 −14673179177
 +307286398400
PR0.0002440.811
 −193108237241
 +260251340336
HER-20.0032030.052
 −340300441468
 +11359136109
Ki67<0.00010.813
 −25693304308
 +197266273269
ALT (U/L)0.0000380.008
 ≤40382257487446
 >407110290131
AST (U/L)0.0040.224
 ≤40394281499483
 >4059787894

HER-2 positive: testing by immunohistochemical (IHC) assay (3+) or in situ hybridization (ISH) assay (+); HER-2 negative: IHC (−), (1+), and (2+) or ISH (−); ALT: alanine aminotransferase; AST: aspartate transferase. Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.